A phase I/II study of BIT 225 for hepatitis C virus infections.
Phase of Trial: Phase I/II
Latest Information Update: 03 Dec 2015
At a glance
- Drugs BIT 225 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 03 Dec 2015 As of 29 November, 2015, results were published in the Journal of Antimicrobial Chemotherapy, as per Biotron's media release.
- 14 Dec 2009 Promising results have been presented at the 2009 HepDART conference, according to a Biotron Limited media release.
- 06 Oct 2009 Status changed from active, no longer recruiting to completed according to a Biotron media release.